

CURRICULUM VITAE

Jun-ichiro Inoue

The Institute of Medical Science, The University of Tokyo

- 1974--1984 Department of Health Chemistry
Faculty of Pharmaceutical Sciences
The University of Tokyo
- 1984-1989 Associate, Department of Viral Oncology, Cancer Institute
- 1989-1992.2 Post doctoral fellow, Molecular and Virology Laboratory
The Salk Institute (Dr. Inder M. Verma).
- 1992.3-1992.12 Associate, Department of Experimental Pathology,
Cancer Institute
- 1993.1-2000.3 Associate Professor at the Department of Oncology,
The Institute of
Medical Science, The University of Tokyo
- 2000.4-2002.3 Professor, Department of Applied Chemistry
Faculty of Science and Technology, Keio University
- 2002.4- present Professor, Division of Cellular and Molecular Biology,
The Institute of Medical Science, The University of Tokyo

TRAF6-NFκB pathway in cell growth and differentiation

Jun-ichiro Inoue

Signals emanating from IL-1R, some members of the TLR family, RANK, CD40 and XEDAR, activate transcription factors AP-1 through MAP kinase (MAPK) activation and NFκB through IκB kinase (IKK) activation. These kinases are thought to be activated by tumor necrosis factor receptor-associated factor 6 (TRAF6) via some adapter molecules or other kinases. Hence, TRAF6 is required for osteoclast formation, B cell differentiation, lymph node organogenesis, and formation of skin appendices. Furthermore, TRAF6 is involved in signals from LMP1 protein, an oncoprotein of EB virus. Therefore, TRAF6 plays pivotal roles in the regulation of cell growth and differentiation *in vivo*. To understand the molecular mechanisms of TRAF6-mediated signals, we have identified a novel TRAF6-interacting protein, TIFA, a TRAF-interacting protein with a forkhead-associated (FHA) domain, and its inhibitor protein TIFAB. The FHA domain is a motif known to bind directly to phosphothreonine and phosphoserine. In transient transfection assays, TIFA activates NFκB and JNK. However, TIFA carrying a mutation that abolishes TRAF6 binding or mutations in the FHA domain that are known to abolish FHA domain binding to phospho-peptide fails to activate NFκB and JNK. Functional interaction of TRAF6 and these proteins will be discussed. In addition, a unique function of the RANK-TRAF6 pathway in formation of osteoclasts, which play a role in bone metastasis of tumor cells will also be presented.